Finland has introduced a faster assessment process for nationally focused clinical trial applications. The Finnish Medicines Agency (Fimea) and the National Committee on Medical Research Ethics (Tukija) now apply a 30-day evaluation timeline that starts at the moment of submission in the portal — not after validation. This provides sponsors with greater predictability and a clearer route to rapid study start-up.
LINK Medical’s own early phase clinics and local experts deliver integrated support — from regulatory and ethics processes to site operations, patient recruitment, and study execution — enabling quicker start-up, consistent quality, and credible data for global development programs.
With dedicated early-phase units, an established healthy volunteer and patient network, and strong experience in areas such as CNS and metabolic research, our Finnish teams are built to translate plans into first-patient-in — fast and reliably.
Together with the new 30-day assessment model, this enables faster start-up, consistent quality, and credible data for global development programs.
Read more about the new process from Fimea.
Contact us to discuss how to accelerate your clinical program in Finland and across the Nordics.